Skip to main content

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

The Original Article was published on 07 September 2022

Correction: BMC Cancer 22, 960 (2022)

https://doi.org/10.1186/s12885-022-09895-5

Following publication of the original article [1], the authors identified that Behrouz Najafi was omitted as the third author in the author group. The author group in this correction article has been updated and the original article [1] has been corrected.

Reference

  1. Allahyari A, Ehsanpour A, Najafi B, et al. Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. BMC Cancer. 2022;22:960. https://doi.org/10.1186/s12885-022-09895-5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Safa Najaf.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Allahyari, A., Ehsanpour, A., Najafi, B. et al. Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. BMC Cancer 22, 1348 (2022). https://doi.org/10.1186/s12885-022-10455-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-022-10455-0